• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Hypersensitivity vasculitis associated with leuprolide (Lupron).

作者信息

Gnanaraj Joseph, Saif Muhammad Wasif

机构信息

Internal Medicine Residency Program, Assistant Program Director, Griffin Hospital, Derby, CT, USA.

出版信息

Cutan Ocul Toxicol. 2010 Sep;29(3):224-7. doi: 10.3109/15569527.2010.487505.

DOI:10.3109/15569527.2010.487505
PMID:20470239
Abstract

Leuprolide (Lupron) is a synthetic analog of naturally occurring gonadotropin-releasing hormone (GnRH). Leuprolide is used as a hormonal antagonist in the treatment of advanced prostatic cancer, and as hormonal therapy in the treatment of endometriosis. Off-label, it is also used in premenopausal or perimenopausal women with hormone-responsive breast cancer for the purpose of ovarian ablation. Ever since its FDA approval in 1985, many adverse reactions have been reported in association with leuprolide ranging from local skin irritation to severe anaphylactoid reactions. In this case report, we present a case of hypersensitivity vasculitis (serum sickness) in a patient who received leuprolide for his prostate cancer. Serum sickness has never been reported as a side-effect of leuprolide. Our case is the first case of serum sickness associated with leuprolide. We emphasize that physicians using leuprolide should be wary of signs and symptoms of hypersensitivity vasculitis or serum sickness.

摘要

相似文献

1
Hypersensitivity vasculitis associated with leuprolide (Lupron).
Cutan Ocul Toxicol. 2010 Sep;29(3):224-7. doi: 10.3109/15569527.2010.487505.
2
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.地加瑞克的疗效与安全性:一项针对前列腺癌患者的为期12个月的、比较性、随机、开放标签、平行组III期研究。
BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x.
3
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.地加瑞克 240/80 毫克:晚期前列腺癌患者的一种新治疗选择。
Expert Rev Anticancer Ther. 2009 Dec;9(12):1737-43. doi: 10.1586/era.09.150.
4
Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.一名前列腺癌患者在接受促性腺激素释放激素激动剂治疗后发现垂体腺瘤。
Int J Urol. 2006 Jan;13(1):87-8. doi: 10.1111/j.1442-2042.2006.01237.x.
5
Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy.
Psychopharmacol Bull. 1997;33(2):311-6.
6
What should I know about Lupron Depot for treating prostate cancer?
Johns Hopkins Med Lett Health After 50. 2012 Jan;23(11):7.
7
Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide.每月给予地加瑞克或亮丙瑞林进行雄激素剥夺治疗的前列腺癌患者出现热潮红。
Prostate Cancer Prostatic Dis. 2011 Jun;14(2):184-90. doi: 10.1038/pcan.2011.11. Epub 2011 Mar 29.
8
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.帕米膦酸盐预防前列腺癌雄激素剥夺治疗期间的骨质流失。
N Engl J Med. 2001 Sep 27;345(13):948-55. doi: 10.1056/NEJMoa010845.
9
Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?皮下缓释注射用醋酸亮丙瑞林:疼痛感会减轻吗?
Expert Rev Anticancer Ther. 2005 Aug;5(4):605-11. doi: 10.1586/14737140.5.4.605.
10
Hemothorax after Lupron therapy of a patient with pleural endometriosis--a case report and literature review.
Int J Fertil Menopausal Stud. 1996 Jan-Feb;41(1):53-5.

引用本文的文献

1
Leukocytoclastic Vasculitis as an Initial Indicator of Prostate Cancer: A Case Report.白细胞碎裂性血管炎作为前列腺癌的首发表现:病例报告。
Am J Case Rep. 2024 Nov 9;25:e944698. doi: 10.12659/AJCR.944698.
2
Transient synovitis associated with leuprolide depot (Lupron).与亮丙瑞林微球(Lupron)相关的短暂性滑膜炎。
Endocrinol Diabetes Metab Case Rep. 2024 Aug 16;2024(3). doi: 10.1530/EDM-24-0031. Print 2024 Jul 1.
3
Evaluation of Hypersensitivity Reactions with Leuprolide Acetate and Triptorelin Acetate in Children.醋酸亮丙瑞林和醋酸曲普瑞林在儿童中引起的超敏反应评估
Indian J Endocrinol Metab. 2021 Nov-Dec;25(6):527-531. doi: 10.4103/ijem.ijem_333_21. Epub 2022 Feb 17.
4
Vasculitis-like Palpable Purpuric Rash Induced by Decapeptyl in a Pediatric Patient Diagnosed Central Precocious Puberty.Decapeptyl 致儿科患者血管炎样可触及紫癜性皮疹,该患者诊断为中枢性性早熟。
J Clin Res Pediatr Endocrinol. 2023 Aug 23;15(3):307-311. doi: 10.4274/jcrpe.galenos.2021.2021.0205. Epub 2021 Nov 12.
5
Long-term effects and significant Adverse Drug Reactions (ADRs) associated with the use of Gonadotropin-Releasing Hormone analogs (GnRHa) for central precocious puberty: a brief review of literature.与使用促性腺激素释放激素类似物(GnRHa)治疗中枢性性早熟相关的长期影响和显著药物不良反应(ADR):文献简要综述
Acta Biomed. 2019 Sep 6;90(3):345-359. doi: 10.23750/abm.v90i3.8736.
6
Persistent Alopecia in a Breast Cancer Patient Following Taxane Chemotherapy and Adjuvant Endocrine Therapy: Case Report and Review of Post-treatment Hair Loss in Oncology Patients with Breast Cancer.一名乳腺癌患者在接受紫杉烷化疗和辅助内分泌治疗后出现持续性脱发:病例报告及乳腺癌肿瘤患者治疗后脱发情况综述
Cureus. 2018 Jul 27;10(7):e3056. doi: 10.7759/cureus.3056.
7
Bullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin: a case report and review of the literature.大疱性出血性皮肤病是全剂量低分子量肝素一种未被充分认识的副作用:一例病例报告及文献复习
Exp Hematol Oncol. 2018 Jul 6;7:15. doi: 10.1186/s40164-018-0108-7. eCollection 2018.
8
Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment.一名接受促性腺激素释放激素激动剂治疗的儿童出现假性脑瘤表现。
J Clin Res Pediatr Endocrinol. 2016 Sep 1;8(3):365-7. doi: 10.4274/jcrpe.2212. Epub 2016 Apr 18.
9
A Case of Gonadotropin-Releasing Hormone Agonist-Induced Sterile Abscess Showing a Good Response to Systemic Steroid Therapy.一例促性腺激素释放激素激动剂诱导的无菌性脓肿对全身类固醇治疗反应良好
Ann Dermatol. 2015 Aug;27(4):460-2. doi: 10.5021/ad.2015.27.4.460. Epub 2015 Jul 29.